Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors

Fecha de publicación: 01/02/2023 Fecha Ahead of Print: 01/01/2023

Autores de IDIVAL

Paula Iruzubieta Coz

Autor

paula.iruzubieta@scsalud.es
María José García García

Autor

mjose.garciag@scsalud.es
Marta Pascual Sáez

Autor

marta.pascual@unican.es
Beatriz Castro Senosiain

Autor

beatriz.castros@scsalud.es
Enrique García Nieto

Autor

egarcia@idival.org
Soraya Curiel Del Olmo

Autor

scuriel@idival.org
María Luisa Cagigal Cobo

Autor

mluisa.cagigal@scsalud.es
José Ignacio Fortea Ormaechea

Autor

joseignacio.fortea@scsalud.es
José Pedro Vaqué Díez

Autor

jpvaque@idival.org
Montserrat Rivero Tirado

Autor

montserrat.rivero@scsalud.es
María Teresa Arias Loste

Autor

mteresa.arias@scsalud.es
Javier Crespo García

Autor

javier.crespo@scsalud.es

Autores ajenos al IDIVAL

Rodriguez-Duque JC
Calleja JL
Hernández-Conde M
Rivas-Rivas C
Vera MI
García-Blanco A
Lopez-Montejo L
Fernández-Lamas T
Rasines L
Frias Y

Abstract

BACKGROUND & AIMS: There is conflicting evidence regarding the prevalence of and risk factors for metabolic-associated fatty liver disease (MAFLD) in patients with inflammatory bowel disease (IBD). We aimed to determine MAFLD prevalence and risk factors in IBD patients.METHODS: Cross-sectional, case-control study included all consecutive IBD patients treated at 2 different university hospitals. Controls were subjects randomly selected from the general population and matched by age, sex, type 2 diabetes status, and body mass index in a 1:2 ratio. MAFLD was confirmed by controlled attenuation parameter. Liver biopsies were collected when MAFLD with significant liver fibrosis was suspected. In addition, age-and fibrosis stage-paired non-IBD patients with biopsy-proven MAFLD served as a secondary control group.RESULTS: Eight hundred thirty-one IBD patients and 1718 controls were included. The prevalence of MAFLD and advanced liver fibrosis (transient elastography double dagger 9.7 kPa) was 42.00% and 9.50%, respectively, in IBD patients and 32.77% and 2.31%, respectively, in the general population (P < .001). A diagnosis of IBD was an independent predictor of MAFLD (adjusted odds ratio, 1.99; P < .001) and an independent risk factor for advanced liver fibrosis (adjusted odds ratio, 5.55; P < .001). Liver biopsies were obtained from 40 IBD patients; MAFLD was confirmed in all cases, and fibrosis of any degree was confirmed in 25 of 40 cases (62.5%). Body mass index and type 2 diabetes prevalence were significantly lower in IBD-MAFLD patients than in severity-paired patients with biopsy-proven MAFLD. CONCLUSIONS: MAFLD and liver fibrosis are particularly prevalent in IBD patients, regardless of the influence of classic metabolic risk factors.

Datos de la publicación

ISSN/ISSNe:: 1542-3565, 1542-7714
Tipo:: Article
Páginas:: 406-4147
DOI:: 10.1016/j.cgh.2022.01.039
Enlace a otro recurso:: www.sciencedirect.com

Documentos

No hay documentos

Métricas

Filiaciones

Rodriguez-Duque JC:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Calleja JL:: Gastroenterology and Hepatology Department, University Hospital Puerta de Hierro-Majadahonda, Madrid, Spain
Iruzubieta P:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Hernández-Conde M:: Gastroenterology and Hepatology Department, University Hospital Puerta de Hierro-Majadahonda, Madrid, Spain
Rivas-Rivas C:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Vera MI:: Gastroenterology and Hepatology Department, University Hospital Puerta de Hierro-Majadahonda, Madrid, Spain
Garcia MJ:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Pascual M:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Castro B:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
García-Blanco A:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
García-Nieto E:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Olmo SC:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Cagigal ML:: Pathology Department, University Hospital Marqués de Valdecilla, Santander, Spain
Lopez-Montejo L:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Fernández-Lamas T:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Rasines L:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Fortea JI:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Vaque JP:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Vaque JP:: Molecular Biology Department, University of Cantabria, Santander, Spain
Frias Y:: Gastroenterology and Hepatology Department, University Hospital Puerta de Hierro-Majadahonda, Madrid, Spain
Rivero M:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Arias-Loste MT:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain
Crespo J:: Instituto de Investigación. Group of Clinical and Translational Research in Digestive Diseases Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain

Keywords

MAFLD; Inflammatory Bowel Disease; Liver Fibrosis; Metabolic Syndrome